A strong company can still have a weak expansion configuration
Product quality, European revenue and a credible management team can support an investment case without proving a US-expansion thesis. The expansion introduces separate assumptions about buyers, conversion, execution and time to revenue.
Due diligence should identify which assumptions are evidenced, which remain untested and how capital exposure changes if they fail.
Questions for the investment review
- What US buyer evidence supports the expansion, rather than only the home-market business?
- What triggered the expansion, and does the timing fit the actual operating capacity?
- How does the forecast distinguish interest, pilot activity, contracted revenue and repeatable conversion?
- What is the downside if revenue arrives later, sales costs rise or execution requires more founder time?
- What evidence gates control the next capital commitment, and who owns the decision to pause?
Use a scoped structural assessment
The Risk Verdict delivers a structural risk score and expansion archetype, calibrated outcome probabilities, and capital consequences and the corrective window. Verdicts typically begin at $25,000.
The published model metrics, the prospective validation cohorts and the sample deliverable describe different evidence populations. They must not be combined into an implied success rate for an investment.
A complement to investment judgment
An expansion assessment is not a recommendation to buy or sell a security, a company valuation or a guarantee of return. Legal, financial, technical and other diligence remain separate responsibilities.